Please login to the form below

Not currently logged in
Email:
Password:

Ramprasad Reddy to chair Aurobindo’s US business

Will also step down from position as full-time director

P V Ramprasad Reddy, who resigned as executive chair of the board of Indian firm Aurobindo in June, 2012, has been appointed chair of its US subsidiary, Aurobindo Pharma USA.

The decision was approved by Aurobindo's board of directors in a meeting last week, although the proposal is still subject to further approval from shareholders, with an extraordinary general meeting scheduled for September 27, 2012 to confirm the appointment.

If approved, Ramprasad Reddy will assume his new position on December 1, 2012.

In addition, Aurobindo's board also approved that Ramprasad Reddy relinquish his executive responsibilities as full-time director of the company, although he will continue as non-exectuive director.

Ramprasad Reddy also has roles at several other Aurobindo subsidiaries, which include serving as director of APL Pharma Thai Limited, Aurobindo (Datong) Bio-Pharma and Aurobindo Tongling (Datong) Pharmaceutical.

In 2008, World Pharmaceutical Frontiers named Ramprasad Reddy as one of the 35 most influential people in the pharmaceutical industry.

29th August 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
ApotheCom

ApotheCom is the medical communications division of Huntsworth Health, which is a global family of best-in-class agencies that provide a...

Latest intelligence

MORE MONEY FOR THE NHS – BUT IS THIS THE ANSWER?
Paul Mannu of Cello Health Insight says that politicians opening their pre-election cheque books can’t put the NHS where it needs to be – but pharma can play a major...
Medius Deal Watch
Pharma deals in February 2015
Pfizer and Valeant led the way during a respectable, if not record-breaking, month for mergers, acquisitions and collaborations...
Medius Deal Watch
Medius Deal Watch table for February 2015
The top major pharma mergers, acquisitions and collaborations during the month were led by the Pfizer/Hospira and Salix/Valeant deals...

Infographics